EUVIMEDEUVIMED entdecken
Crossref

Rare Disease Innovation at the FDA—Opportunities for Implementation

Carolyn K Shore, Tequam L Worku, Jeffrey Kahn

JAMA · 17.12.2024 · 332 (23) · 1973

DOI: 10.1001/jama.2024.20358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 17.12.2024. Verfasst von Carolyn K Shore und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Academies of Sciences, Engineering, and Medicine, Washington, DC. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Viewpoint discusses new pathways for researchers to seek collaboration when conducting studies on treatments for rare diseases and conditions.

Autor:innen und Institutionen

  • National Academies of Sciences, Engineering, and Medicine, Washington, DC.
  • Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland.

Zitieren

APA

Shore, C. K., Worku, T. L., & Kahn, J. (2024). Rare Disease Innovation at the FDA—Opportunities for Implementation. JAMA, 332(23), 1973. https://doi.org/10.1001/jama.2024.20358

Vancouver

Shore CK, Worku TL, Kahn J. Rare Disease Innovation at the FDA—Opportunities for Implementation. JAMA. 2024;332(23):1973. doi:10.1001/jama.2024.20358

BibTeX
@article{Shore2024,
  author = {Shore, Carolyn K and Worku, Tequam L and Kahn, Jeffrey},
  title = {Rare Disease Innovation at the FDA—Opportunities for Implementation},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {23},
  pages = {1973},
  doi = {10.1001/jama.2024.20358}
}
Kostenlos starten →